Wide Ranks

BOLT

Bolt Biotherapeutics, Inc.

0.6260

Top Statistics
Market Cap 23 M Forward PE -0.7034 Revenue Growth -11.00 %
Current Ratio 4.28 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.4190 Enterprise / Revenue -2.71 Price To Sales Trailing12 Months 2.15
Profitability
Profit Margins 0.00 % Operating Margins -1492.71 %
Balance Sheet
Total Cash 73 M Total Cash Per Share 1.93 Total Debt 18 M
Total Debt To Equity 22.00 Current Ratio 4.28 Book Value Per Share 2.96
All Measures
Short Ratio 54.00 % Message Board Id finmb_297390520 Shares Short Prior Month 119132
Return On Equity -0.5804 City Redwood City Uuid dff93495-0732-3bf9-90c2-03f27dac1fe3
Previous Close 0.6299 First Trade Date Epoch Utc 1 B Book Value 2.96
Beta 0.9160 Total Debt 18 M Volume 127645
Price To Book 0.2116 Fifty Two Week Low 0.5400 Total Cash Per Share 1.93
Total Revenue 11 M Shares Short Previous Month Date 1 B Target Median Price 1.75
Audit Risk 9 Max Age 86400 Recommendation Mean 3.00
Sand P52 Week Change 0.3133 Operating Margins -1492.71 % Target Mean Price 1.75
Net Income To Common -66166000 Short Percent Of Float 0.0022 Implied Shares Outstanding 38 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 161030
Average Volume10days 161030 Total Cash 73 M Next Fiscal Year End 1 B
Revenue Per Share 0.2940 Held Percent Insiders 0.0346 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 0.6299 Target Low Price 1.50 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.6300 Open 0.6290 Free Cashflow -33362624
State CA Dividend Yield 0.00 % Return On Assets -0.2941
Time Zone Short Name EST Board Risk 9 Trailing Eps -1.71
Day Low 0.6001 Address1 900 Chesapeake Drive Shares Outstanding 38 M
Compensation Risk 8 Price Hint 4 Target High Price 2.00
Website https://www.boltbio.com 52 Week Change -0.2661 Average Volume 139950
Forward Eps -1.28 Recommendation Key hold Compensation As Of Epoch Date 1 B
Quick Ratio 412.80 % Is_sp_500 False Regular Market Day High 0.6400
Profit Margins 0.00 % Debt To Equity 22.00 Fifty Two Week High 1.56
Day High 0.6400 Shares Short 65990 Regular Market Open 0.6290
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue -2.71
Revenue Growth -11.00 % Shares Percent Shares Out 0.0017 Operating Cashflow -63907000
Currency USD Time Zone Full Name America/New_York Market Cap 23 M
Is_nasdaq_100 False Zip 94063 Quote Type EQUITY
Industry Biotechnology Long Name Bolt Biotherapeutics, Inc. Overall Risk 9
Regular Market Day Low 0.6001 Held Percent Institutions 0.5819 Current Price 0.6260
Enterprise To Ebitda 0.4190 Financial Currency USD Current Ratio 4.28
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 25 M Two Hundred Day Average 0.8499 Governance Epoch Date 1 B
Enterprise Value -30247624 Price To Sales Trailing12 Months 2.15 Forward PE -0.7034
Regular Market Volume 127645 Ebitda -72229000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.

The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.

It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.

The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F.

Hoffmann-La Roche Ltd; and license agreement with Stanford University.

The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.

Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.